Oncobiologics, Huahai in biosimilars deal

Oncobiologics Inc. (Cranbury, N.J.) and Zhejiang Huahai Pharmaceutical Co. Ltd. (Shanghai:600521) partnered to co-develop and commercialize four biosimilars. The biologics are autoimmune drug Humira adalimumab; autoimmune and cancer drug Rituxan rituximab; and cancer drugs Avastin bevacizumab and Herceptin trastuzumab. Huahai will have exclusive rights to market the biosimilars in China; the companies said they plan to seek ex-Chinese commercialization partners. The partners plan to launch their first biosimilar by late 2016, but did not disclose details. The partners also are not disclosing financial terms. ...